Bacil Pharma to set up wholly-owned R&D subsidiary
Bacil Pharma Limited has announced its proposal to incorporate a wholly-owned subsidiary, Bacil Research & Development Private Limited, to focus on research and development activities. The incorporation is subject to necessary approvals from the Registrar of Companies and other statutory authorities. The subsidiary will operate as a private limited company.
*this image is generated using AI for illustrative purposes only.
bacil pharma proposes to incorporate a wholly-owned subsidiary named Bacil Research & Development Private Limited to strengthen its research and development capabilities. The new entity will be established as a private limited company and will focus on undertaking R&D activities and other allied operations permitted under applicable laws. The incorporation is subject to approval from the Registrar of Companies and other relevant statutory authorities.
The Board of Bacil Pharma Limited has identified the need for a dedicated subsidiary to drive its research initiatives. This strategic move aims to enhance the company's focus on developing new products and technologies. The subsidiary will operate entirely under the ownership of Bacil Pharma Limited, ensuring direct control over its research outcomes.
Key Details of the Proposed Subsidiary
| Detail | Information |
|---|---|
| Name | Bacil Research & Development Private Limited |
| Structure | Private Limited Company |
| Ownership | Wholly-owned by Bacil Pharma Limited |
| Objective | Research and development activities and allied operations |
| Status | Subject to regulatory approvals |
The intimation was submitted to BSE Limited pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Mrs. Chaitali Kalpataru Shah, Director & CFO of Bacil Pharma Limited, signed the communication regarding the proposal.
Historical Stock Returns for Bacil Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.24% | +3.54% | -19.80% | +21.94% | +16.90% | +498.71% |
What is the estimated timeline for receiving regulatory approvals and commencing operations?
How much capital does Bacil Pharma plan to allocate to the new subsidiary for R&D initiatives?
What specific therapeutic areas or technologies will the new entity prioritize?
19
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
